Results 11 to 20 of about 69,008 (285)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Biomolecules & Biomedicine, 2022
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma.
Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin , Denizcan Güven , Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan , Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker , Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç , Abdullah Sakin , Haci Mehmet Türk, Dilek Çağlayan , Şener Cihan, Yusuf Açikgöz , Doğan Uncu   +33 more
doaj   +1 more source

A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

EBioMedicine, 2020
Background: Pertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally found ...
Xiaoyu Ding, Wanjian Gu, Yujie Zhong, Xiaoyao Hao, Jinyu Liu, Shukai Xia, Lan Luo, Mingjiu Chen, Chunni Zhang   +8 more
doaj   +1 more source

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Scientific Reports, 2021
Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal ...
Nagarajan Vinod, Jae Hyung Kim, Seungbum Choi, Ilhan Lim   +3 more
doaj   +1 more source

Current perspective – Trastuzumab [PDF]

European Journal of Cancer, 2009
This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.
Hall, P.S., Cameron, D.A.
openaire   +3 more sources

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

EJNMMI Radiopharmacy and Chemistry, 2023
Background Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain.
Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan, Raymond M. Reilly   +4 more
doaj   +1 more source

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells

BMC Cancer, 2023
Background Trastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive gastric cancer; however, trastuzumab resistance is a major problem in clinical practice.
Yuna Kim, Yoo Jin Bae, Jie-Hyun Kim, Hyunki Kim, Su-Jin Shin, Da Hyun Jung, Hyojin Park   +6 more
doaj   +1 more source

Trastuzumab

Women's Health, 2005
Breast cancer is a heterogenous disease with several clinical and biologic subtypes. Human epidermal growth factor receptor 2 (HER 2) is overexpressed in approximately 20% of breast cancers. This overexpression is usually due to HER 2 gene amplification, and results in a more aggressive tumor with a worse prognosis.
Ian E, Smith, Susan G, Cross
openaire   +2 more sources

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft

Cell Death Discovery, 2022
Acquired Trastuzumab resistance is a complicated and disastrous event for HER2-positive gastric cancer (GC). In this study, we successfully established a GC PDX model with Trastuzumab sensitivity (176P) and induced a homologous model with acquired ...
Mengqi Zhang, Beifang Li, Haiyan Liao, Zuhua Chen, Wenwen Huang, Jing Yang, Sai Ge, Zhongwu Li, Lin Shen, Cheng Zhang, Jing Gao   +10 more
doaj   +1 more source

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review

Frontiers in Pharmacology, 2023
Background: Studies confirmed that trastuzumab plus fluorouracil-based chemotherapy improves the survival to more than 1 year in human with human epidermal growth factor receptor-2 (HER2)-positive advanced gastric cancer. However, there are still a small
Huifang Lv, Yunduan He, Caiyun Nie, Feng Du, Xiaobing Chen   +4 more
doaj   +1 more source

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates. [PDF]

Biomed Chromatogr
ABSTRACT Antibody‐drug conjugates (ADCs) are innovative drugs composed of cytotoxic molecules (payload) linked to antibodies, that selectively target and kill cancer cells upon internalization. In vivo, ADCs exist as intact molecules, naked antibodies, or released, unconjugated (linker‐)payload.
Buitelaar PLM, Rosing H, Beijnen JH, Steeghs N, Huitema ADR.   +4 more
europepmc   +2 more sources